Silence Therapeutics plc (SLNCF)
OTCMKTS · Delayed Price · Currency is USD
1.600
0.00 (0.00%)
Feb 17, 2026, 9:30 AM EST
Silence Therapeutics Revenue
Silence Therapeutics had revenue of $159.00K in the quarter ending September 30, 2025, a decrease of -89.39%. This brings the company's revenue in the last twelve months to $25.83M, up 18.13% year-over-year. In the year 2024, Silence Therapeutics had annual revenue of $41.20M with 27.54% growth.
Revenue (ttm)
25.83M
Revenue Growth
+18.13%
P/S Ratio
8.89
Revenue / Employee
222.67K
Employees
116
Market Cap
229.56M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41.20M | 8.90M | 27.54% |
| Dec 31, 2023 | 32.30M | 10.65M | 49.17% |
| Dec 31, 2022 | 21.66M | 4.87M | 29.01% |
| Dec 31, 2021 | 16.78M | 9.29M | 124.07% |
| Dec 31, 2020 | 7.49M | 7.17M | 2,215.11% |
| Dec 31, 2019 | 323.57K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 21.62K | -928.69K | -97.72% |
| Dec 31, 2016 | 950.31K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 23.37K | -170.40K | -87.94% |
| Dec 31, 2013 | 193.77K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| Harvard Apparatus Regenerative Technology | 743.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 198.11K |
Silence Therapeutics News
- 2 months ago - Silence Therapeutics CEO Craig Tooman steps down - Seeking Alpha
- 2 months ago - Leadership Transition at Silence Therapeutics (SLN): CEO Craig Tooman Departs - GuruFocus
- 2 months ago - Silence Therapeutics CEO Tooman to depart; Chairman Ross to lead on interim basis - Seeking Alpha
- 2 months ago - Silence Therapeutics Announces Leadership Changes - Business Wire
- 3 months ago - Silence Therapeutics: Divesiran Targets High-Burden PV - Seeking Alpha
- 3 months ago - Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference - Business Wire
- 3 months ago - Silence Therapeutics plc Non-GAAP EPS of -$0.15, revenue of $0.16M - Seeking Alpha
- 3 months ago - Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Business Wire